PATENT CLAIM ANALYSIS

Application Number: 16014818
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "085100"]

Abstract:
The present invention provides compositions comprising as an essential feature granulocyte-macrophage colony-stimulating factor (GM-CSF) together with fosfomycin for the treatment of bacterial lung infections by administration via the air-ways.

Claim (Index 9):
The method of  claim 2 , wherein the pharmaceutical composition is administered in a period of 6 days to 15 days.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 94.0
- Lexical Diversity: 1.03226
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15328426', '14009855', '11914599', '12923363', '14006854']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7173888067954088
- 35 USC 102 Novelty (BERT): 0.515701938319941
- Combined Prediction Score: 0.6972201199478621
- Mean Citation Score: 192.54219200000003
- Max Citation Score: 210.17184
- Similarity Product: 109.63420204467774

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test